Thermo Fisher Live Event Shorts

  1. Clinical Trial Strategy And ADC Dev Partnership 4/29/2025

    As the Bioprocess Online Live panel discussion Accelerating ADC Process Development wraps up, expert panelists Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) address audience questions on AI-driven stratification of patients and biomarkers in clinical patient enrollment and IP strategies and collaboration.

  2. ADC Heterogeneity, Site-Specific Conjugation 4/29/2025

    This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipophilic toxicity, homogeneity, computational tools to address molecular design and ADC behavior, and revisiting strategic considerations in CDMO selection before addressing a second live poll of our audience. 

  3. Linker And ADC Platform Manufacturing Technologies 4/29/2025

    In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, Dr. Léo Marx (Debiopharm) addresses advances in linker technology before he, Dr. Monika Lamba Saini (ADC Therapeutics) and Dr. Philipp Spycher (Araris Biotech) answer audience questions about the feasibility of developing a platform for ADC development, IP considerations for proprietary technologies, and outsourcing vs. in-house manufacturing approaches.

  4. Challenges In ADC Process Development 4/29/2025

    Where does ADC process development fail? In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) address audience questions on target identification cleanliness and payload challenges before we turn the tables on the audience with a question on their biggest challenges.

  5. AI In ADC Target Identification 4/29/2025

    How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clinical implications of target expression and internalization, and AlphaFold AI-driven pathology in this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development.

  6. ADCs & Speed To IND 4/29/2025

    In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC development challenges—including molecular complexity, regulatory and analytical hurdles, and strategic logistical manufacturing. We discuss those challenges in the context of the burgeoning industry’s breakneck development timelines leading up to IND submission.

  7. Outsourcing Considerations For Novel Protein Therapeutics 9/13/2024

    Panelists discuss special considerations for outsourcing the development and manufacturing of novel, complex protein therapeutics in this Bioprocess Online Live event.

  8. Addressing Aggregation And Degradation In Complex Protein Therapeutics 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss using a transient expression platform to make fast early product attribute decisions.

  9. When To Conduct Analytical Assays In Novel Protein Therapeutic Development 9/13/2024

    Panelists in the Bioprocess Online Live event discuss the various points at which analytical assays are most critical during complex protein therapeutic development.

  10. IND Prep Versus Clinical/Commercial Scale-Up In Novel Protein Therapeutics 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists share detailed considerations for scale-up of complex protein therapeutics.